Avexxin’s lead compound AVX001 in a topical formulation has shown Proof-of-Concept in man in an ascending dose Phase I/IIa study encompassing 26 patients suffering from mild-to-moderate psoriasis. The independent Safety Board concluded that the treatment was safe for the patients at the dose levels employed.
Avexxin completes series B round financing Avexxin AS has completed a series B round financing facilitated by Sparebank1 SMN Markets, Norway, with new investors joining existing stakeholders Sarsia Seed and Leiv Eiriksson Nyskaping. Trondheim, Norway, November 12, 2012 – Avexxin AS, a company focusing on the development of novel small molecule therapeutics for patients suffering […]
In October 2012, Windhover Conferences together with the publishers of In Vivo, Startup and the Pink Sheet appointed Avexxin to receive the honor of being chosen as one of the Top 10 Autoimmune/Anti-Inflammatory companies/Projects to Watch, see www.tapartnerships.com. Avexxin is honored and pleased to receive this nomination
Avexxin receives series a second tranche Financing will be used to advance Avexxin’s lead compound against psoriasis. Proof-of-Concept trial in man is expected to commence late 2012. Trondheim, Norway, January 5, 2012 – Avexxin AS, a company focusing on the development of novel small molecule therapeutics for patients suffering from chronic inflammatory conditions, announces the […]
AVEXXIN CLOSES FINANCING ROUND Avexxin is closing series A financing round enabling the company to take its lead compound forward through clinical trial phase I/IIa. Financing will be used to develop Avexxin’s lead compound against psoriasis through clinical phase I/IIa Trondheim, January 10, 2011 – Avexxin AS, a Norwegian pharma company focusing on the development […]
Avexxin has been granted a significant financial support by the Norwegian Research Council to expand its activities in chemistry and drug discoveries in new indications in chronic inflammatory diseases.
Avexxin has entered into an R&D contract with the University of Bern, Prof. Andrea Huwiler at the Institute of Pharmacology, regarding investigation of Avexxin compounds in glomerulonephritis.
Avexxin has expanded its R&D collaboration with Synthetica AS, a highly skilled SME in Oslo within organic chemistry.
NFR has granted Avexxin important financial support to expand its activities in chemistry and drug discovery in new indications in chronic inflammatory diseases.
Avexxin AS was incorporated as a spin off from Leiv Eirikssen Nyskaping AS on the basis of basic research conducted at the Norwegian University of Science and Technology under the leadership of Professor Berit Johansen at the Department of Biology.